Aim: To evaluate the efficacy and safety of using a syringe driver perfusor pump to deliver frequent regular bolus doses of rFVIIa peri- and postoperatively to patients with severe haemophilia and inhibitors. Background: The provision of surgical haemostatic coverage with rFVIIa requires regular bolus doses, initially every two hours and subsequently three-hourly, moving to four- to six-hourly post-operatively. This has implications for safety and nursing time, and can influence clinical decision-making. We investigated the use of an infusion pump to deliver timed and accurate rFVIIa bolus doses during the postoperative period. Methods: Two patients with severe haemophilia A and inhibitors undergoing three procedures were managed with a pre-surgical bolus infusion of 120mcg/kg of rFVIIa, followed by postoperative doses of 90mcg/kg every two hours for the first 72 hours, and every three hours subsequently, with increasing dose intervals thereafter. All postoperative bolus doses were delivered via a pre-programmed infusion pump. The pump also required a constant background infusion set at 0.1ml/ hour for the first patient, and reduced to 0.01ml/hour for the second patient. Results: The pump was simple to use and readily accepted by patients and nursing staff. There were no delayed or missed doses, and good haemostasis was maintained. Overall nursing time involved in reconstituting and administering rFVIIa was reduced from three to six hours per treatment day (with conventional bolus dosing) to just one to two hours per day with the pump. Conclusions: The syringe pump successfully delivered the correct doses at the specified time intervals for all three procedures. The technique met the centre’s safety and efficacy criteria and resulted in a significant reduction in the amount of nursing time needed over a 24-hour period. This novel method of rFVIIa administration appears to be safe and effective in the elective surgery setting, and should be further investigated.
1. Giangrande PL, Wilde JT, Madan B, et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophiliac patients with inhibitors. Haemophilia 2009;15(2): 501-8.
2. Nursing and Midwifery Council. Standards for Medicine Management. 2015. Available from: https://www.nmc.org.uk/globalassets/sitedocuments/standards/nmc-standards-formedicines-management.pdf (accessed 24 November 2016).
3. Lee CA, Kessler CM, Varon D, et al. Safety, efficacy and lessons from continuous infusion with rFVIIa. Haemophilia 1998; 4(4): 564-7.
4. Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD, et al. Recombinant Factor VIIa Data Collection Group. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors. Haemophilia 2002; 8(5): 649-56.
5. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
6. Monroe DM Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9(Suppl 1): S15-20.
7. Christensen A, Jensen JT, Nøhr AM, Cooper DL. Roomtemperature- stable recombinant activated coagulation factor VII recombinant: chemical and microbiologic stability over 24 hours during continuous in vitro infusion. Clin Ther 2011; 33:1 997-2001.
8. Nedergaard H, Vestergaard S, Theil Jensen P, et al. In vitro Stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature. Clin Therapeutics 2008; 30(7): 1309-15.
9. Baudo F, Redaelli R, Caimi TM, et al. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 2000; 9: 21-24.
10. NovoSeven [summary of product characteristics]. 2014. Available at: https://www.medicines.org.uk/emc/medicine/21171 (accessed 24 November 2016).